Hsiao-Li Wu1, Tung-Yueh Chuang1, Ayman Al-Hendy1, Michael P Diamond1, Ricardo Azziz2, Yen-Hao Chen3. 1. Department of Obstetrics and Gynecology, Georgia Regents University, Augusta, Georgia. 2. Department of Obstetrics and Gynecology, Georgia Regents University, Augusta, Georgia; Department of Medicine, Georgia Regents University, Augusta, Georgia. 3. Department of Obstetrics and Gynecology, Georgia Regents University, Augusta, Georgia. Electronic address: yechen@gru.edu.
Abstract
OBJECTIVE: To determine whether berberine (BBR), a naturally occurring plant-derived alkaloid, inhibits the proliferation of human uterine leiomyoma (UtLM) cells. DESIGN: Laboratory research. SETTING: Laboratory. PATIENT(S): UtLM and normal human uterine smooth muscle (UtSMC) cell lines. INTERVENTION(S): Treatment with [1] BBR (10, 20, and 50 μM), [2] BBR (20 and 50 μM) and/or 17β-estradiol (E2; 10 and 100 nM), and [3] BBR (20 and 50 μM) and/or progesterone (P4; 10 and 100 nM) for 24 or 72 hours. MAIN OUTCOME MEASURE(S): Cell proliferation, cell cycle, apoptosis, and related genes expression were determined. RESULT(S): BBR inhibited UtLM cell proliferation by inducing G2/M cell cycle arrest and apoptosis. Cell cycle G2/M phase-related genes were altered by BBR treatment: the expression of cyclin A1, cyclin B1, and Cdk1 were down-regulated, while Cdk4, p21, and p53 were up-regulated. BBR-treated cells stained positively for annexin V and manifested increased BAX expression. E2- and P4-induced UtLM cell proliferation was blocked by BBR treatment. In marked contrast, even the highest concentration of BBR (50 μM) did not influence cell proliferation in UtSMC cells. CONCLUSION(S): BBR selectively inhibits cellular proliferation and blocks E2- and P4-induced cell proliferation in UtLM but not in normal UtSMC cells. In addition, BBR did not demonstrate cytotoxicity effects in normal human UtSMCs. Our results suggest BBR could be a potential therapeutic agent for the treatment of uterine leiomyoma.
OBJECTIVE: To determine whether berberine (BBR), a naturally occurring plant-derived alkaloid, inhibits the proliferation of human uterine leiomyoma (UtLM) cells. DESIGN: Laboratory research. SETTING: Laboratory. PATIENT(S): UtLM and normal human uterine smooth muscle (UtSMC) cell lines. INTERVENTION(S): Treatment with [1] BBR (10, 20, and 50 μM), [2] BBR (20 and 50 μM) and/or 17β-estradiol (E2; 10 and 100 nM), and [3] BBR (20 and 50 μM) and/or progesterone (P4; 10 and 100 nM) for 24 or 72 hours. MAIN OUTCOME MEASURE(S): Cell proliferation, cell cycle, apoptosis, and related genes expression were determined. RESULT(S): BBR inhibited UtLM cell proliferation by inducing G2/M cell cycle arrest and apoptosis. Cell cycle G2/M phase-related genes were altered by BBR treatment: the expression of cyclin A1, cyclin B1, and Cdk1 were down-regulated, while Cdk4, p21, and p53 were up-regulated. BBR-treated cells stained positively for annexin V and manifested increased BAX expression. E2- and P4-induced UtLM cell proliferation was blocked by BBR treatment. In marked contrast, even the highest concentration of BBR (50 μM) did not influence cell proliferation in UtSMC cells. CONCLUSION(S): BBR selectively inhibits cellular proliferation and blocks E2- and P4-induced cell proliferation in UtLM but not in normal UtSMC cells. In addition, BBR did not demonstrate cytotoxicity effects in normal human UtSMCs. Our results suggest BBR could be a potential therapeutic agent for the treatment of uterine leiomyoma.
Authors: James A McCubrey; Kvin Lertpiriyapong; Linda S Steelman; Steve L Abrams; Li V Yang; Ramiro M Murata; Pedro L Rosalen; Aurora Scalisi; Luca M Neri; Lucio Cocco; Stefano Ratti; Alberto M Martelli; Piotr Laidler; Joanna Dulińska-Litewka; Dariusz Rakus; Agnieszka Gizak; Paolo Lombardi; Ferdinando Nicoletti; Saverio Candido; Massimo Libra; Giuseppe Montalto; Melchiorre Cervello Journal: Aging (Albany NY) Date: 2017-06-12 Impact factor: 5.682
Authors: Sabrina Saurin; Myriam Meineck; Gerhard Erkel; Till Opatz; Julia Weinmann-Menke; Andrea Pautz Journal: Pharmaceuticals (Basel) Date: 2022-04-20